01 January 2008
Comparing graft function for tacrolimus- and cyclosporine-treated patients. A long-term comparative study involving nephrotoxicity markers
Z. Marchewka, J. Kuźniar, K. Falkiewicz, B. Szymańska, M. Zynek-Litwin, D. Patrzałek, A. Długosz, M. KlingerAnn Transplant 2008; 13(1): 43-43 :: ID: 880211
Abstract
Background: The study compares the effect of cyclosporine and tacrolimus treatment on the transplanted kidney.
Material/Methods: This is done by examining nephrotoxicity markers in urine: lysosomal enzymes of proximal tubular cells (NAG, NAG-B, GAL, b-Gr) and brush border enzymes (AAP, GGT). The study involved 120 CsA-treated and 99 TAC-treated patients. Patients groups were identified depending on the time since transplantation (I - up to 1 year after transplantation; II - 1-2 years; III - 2-3 years; IV - more than 3 years). The control group consisted of 31 healthy people. Urine marker levels for CsA- and TAC-patients were examined in each group. For each group the study focused on correlation between markers' density and graft function as well as between CsA and TAC whole blood levels and the enzymes activity.
Results: In TAC group the time from transplantation was found to correlate negatively with creatinine level. No such association was found for CsA-treated group. NAG and NAG-B urine activity was significantly lower in control group. Peak enzyme activity for both CsA- and TAC-treated patients occurred in group I. As for groups III and IV, NAG-B excretion was found higher for the CsA group. NAG activity in urine and serum creatinine level were correlated significantly in CsA group (p<0.05). Similar correlation was found in TAC-group, but it was not significant. NAG urine activity was shown to correlate negatively with the time after transplantation (p<0.001) in TAC group.
Conclusions: The study favours tacrolimus-based treatment.
NAG and NAG-B appear to be the best CsA and TAC nephrotoxicity markers.
Keywords: Cyclosporine, Tacrolimus, Cerebral Palsy, Factor V Leiden mutation, Prothrombin G20210A mutation,
In Press
Original article
Prediction of Renal Graft Function 1 Year After Adult Deceased-Donor Kidney Transplantation Using Variables...Ann Transplant In Press; DOI: 10.12659/AOT.944603
Original article
Impact of Donor-Recipient Relationship on Long-Term Outcomes in Living-Related Donor Kidney TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.945065
Case report
Successful Interventional Therapy for Portal Vein Stenosis after Ex Vivo Liver Resection and Autotransplant...Ann Transplant In Press; DOI: 10.12659/AOT.944851
Original article
Urinary Chemokines CXCL9 and CXCL10 Are Non-Invasive Biomarkers of Kidney Transplant RejectionAnn Transplant In Press; DOI: 10.12659/AOT.944762
Most Viewed Current Articles
05 Apr 2022 : Original article 12,880
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 9,836
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,289
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,052
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860